Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 370,739,776
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.82
  • Price/Sales 5.19
  • Price/Cash Flow 16.78
  • Price/Book 5.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
137.74 +0.14%
on 11/20/17
144.35 -4.45%
on 10/23/17
-4.47 (-3.14%)
since 10/20/17
3-Month
129.05 +6.88%
on 09/29/17
144.35 -4.45%
on 10/23/17
+5.30 (+4.00%)
since 08/18/17
52-Week
109.32 +26.17%
on 12/07/16
144.35 -4.45%
on 10/23/17
+22.57 (+19.56%)
since 11/18/16

Most Recent Stories

More News
Risperdal Gynecomastia Lawsuit Headed for New Trial After Pennsylvania Superior Court Overturns Defense Verdict, Bernstein Liebhard LLP Reports

A Plaintiff who claims to have developed gynecomastia due to his use of Risperdal will get a new trial, after a three-judge panel of the Pennsylvania Superior Court reversed the only verdict favoring Johnson...

JNJ : 137.93 (-0.05%)
Global Intraocular Lenses Strategic Market 2016-2024 - Leading Players are Alcon, Bausch & Lomb, Johnson & Johnson Vision Care, Zeiss

The "Intraocular Lenses - Global Strategic Business Report" report has been added to Research and Markets' offering.

JNJ : 137.93 (-0.05%)
Johnson & Johnson to Participate in the Citi 2017 Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Citi 2017 Global Healthcare Conference on Thursday, Dec. 7, at Lotte New York Palace, NY. Joaquin Duato, Executive Vice President, Worldwide Chairman,...

JNJ : 137.93 (-0.05%)
Johnson & Johnson Innovation Announces Winner of its Advancing the Safe Use of Healthcare Products QuickFire Challenge

Johnson & Johnson Innovation LLC today announced developers at CertaDose, Inc. have won its latest QuickFire Challenge: Advancing the Safe Use of Healthcare Products. The challenge called for potentially...

JNJ : 137.93 (-0.05%)
Legal-Bay Pre Settlement Funding Company Announces $247 Million Settlement For Faulty DePuy Pinnacle Hip Replacements

Legal-Bay LLC, The Pre Settlement Lawsuit Funding Company, reports today that a $247 million settlement was awarded to six plaintiffs who experienced numerous problems with their hip-replacement devices....

JNJ : 137.93 (-0.05%)
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with...

TBPH : 28.58 (-4.38%)
INVA : 13.17 (+0.84%)
JNJ : 137.93 (-0.05%)
GSK : 35.12 (+0.17%)
US Anticoagulation Therapy Market to 2022 - Major Players are C. H. Boehringer Sohn, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Daiichi Sankyo and Portola Pharmaceuticals

The "US Anticoagulation Therapy Market - Forecast to 2022" report has been added to Research and Markets' offering.

JNJ : 137.93 (-0.05%)
PTLA : 49.51 (+0.47%)
BMY : 60.80 (-0.85%)
Hip Replacement Lawsuit News: DePuy Pinnacle Plaintiffs Awarded $247 Million At Conclusion of 4th Federal Bellwether Trial, Bernstein Liebhard LLP Reports

Johnson & Johnson and its DePuy Orthopaedics subsidiary have been ordered to pay $247 million to six plaintiffs who experienced the premature failure of a metal-on-metal version of the companies' Pinnacle...

JNJ : 137.93 (-0.05%)
Federal Jury Returns $247 Million Verdict in Defective Hip Implants Case

A federal court jury in Texas returned a $247 million verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson...

JNJ : 137.93 (-0.05%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.38 (-0.24%)
JNJ : 137.93 (-0.05%)
LLY : 83.18 (+0.35%)
PFE : 35.35 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 138.90
1st Resistance Point 138.41
Last Price 137.93
1st Support Level 137.59
2nd Support Level 137.26

See More

52-Week High 144.35
Last Price 137.93
Fibonacci 61.8% 130.97
Fibonacci 50% 126.84
Fibonacci 38.2% 122.70
52-Week Low 109.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart